IP Library Granted Patent US 8,507,465
Granted Patent B2
US 8,507,465 · App. 12/739,880 · Granted Aug 13, 2013

Antiemetic-oral contraceptive combination

Inventors: Sheetal Kulkarni (Pune, IN); Srirupa Das (Pune, IN); Harshal Anil Jahagirdar (Pune, IN); Satish Dalal (Pune, IN); Shirish Kulkarni (Pune, IN)
Assignee: Lupin Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,507,465
App. No.
12/739,880
Granted
Aug 13, 2013
Kind
B2
Abstract

The present invention relates to a method of reducing the incidence of nausea and vomiting associated with the administration of oral contraceptive formulation and a method of preparation of oral contraceptive formulation comprising progestin and/or estrogen and an antiemetic. The preferred oral contraceptive formulation comprises of levonorgestrel and an antiemetic.

Claims (6)

1. An oral pharmaceutical formulation comprising a combination of levonorgestrel and an antiemetic selected from ondansetron or meclizine within the same formulation, wherein levonorgestrel is contained in a delayed release portion comprising at least one delayed release agent selected from the group consisting of hydrophilic or hydrophobic polymers or mixtures thereof, and the antiemetic is contained in an immediate release portion comprising at least one pharmaceutically acceptable excipients, wherein at least 80% of antiemetic is released within 30 min in 0.1 N HCl and at least 80% of levonorgestrel is released within 30 min at pH 6.8, when the dissolution is carried out for 2 hours in 0.1 N HCl followed by pH 6.8 phosphate buffer using a USP Type I apparatus at 100 rpm.

2. The oral pharmaceutical formulation according to claim 1 wherein the antiemetic is selected from ondansetron or meclizine is released at least about 30 minutes prior to the release of Levonorgestrel.

3. The oral pharmaceutical formulation according to claim 1 is selected from the group consisting of granules, sachets, capsules, matrix tablets, layered tablet or coated tablets.

4. The oral pharmaceutical formulation according to claim 1 wherein the levonorgestrel is coated with a delayed release agent selected from an enteric polymer.

5. The oral pharmaceutical formulation according to claim 1 wherein the dose of levonorgestrel is selected from 0.75 mg or 1.5 mg.

6. A method of emergency contraception comprising administering the single oral pharmaceutical formulation according to claim 1 as an emergency contraceptive.

Assignments (2)
CHANGE OF ADDRESS Recorded Jan 27, 2017
From: LUPIN LIMITED
To: LUPIN LIMITED
Reel/Frame 041936/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2010
From: KULKARNI, SHEETAL; DAS, SRIRUPA; JAHAGIRDAR, HARSHAL ANIL; DALAL, SATISH; KULKARNI, SHIRISH
To: LUPIN LIMITED
Reel/Frame 024289/0539 →
Priority Claims (1)
IN 1460/KOL/2007 · Oct 25, 2007 · national
Continuity (1)
Related Publication 20100240626A1 · Sep 23, 2010